Lucid Diagnostics Reports Q3 2026 Results Amid Transition to Medicare Reimbursement
Lucid Diagnostics (LUCD) reported its third quarter 2026 financial results, highlighting a strategic transition toward a Medicare reimbursement model. While EsoGuard revenue remained flat at $1.2 million year-over-year, the company achieved a record monthly test volume of 1,800 tests in October. Total quarterly test volume reached 2,871, representing a 4% sequential increase and meeting management's transitional targets. The company is seeing improved unit economics, with average revenue per test rising to $446 year-to-date compared to $383 in 2025. Despite a GAAP net loss of $6.7 million, the quarterly cash burn reached its lowest level in four quarters at $10.2 million. The company bolstered its liquidity through a Series C preferred stock financing, bringing its pro forma cash position to $33 million.
Tickers: $SPCX
Topics: cash position medicare reimbursement net loss revenue test volume
Read the full article at Motley Fool
Part of the story Lucid Diagnostics Reports Q3 2026 Results Amid Transition to Medicare Reimbursement (8 articles)